Published by
The Street
The Street
By GlobeNewswire 2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and Effective Diagnostic for Frequent Mass TestingSecond-Generation of AptameX Received Full Approval in Indonesia for Five YearsFocus on Completing CE Mark and Commercialization Beyond Indonesia in 2022In 2022, Achiko Looks to Further the Company’s Growth, Proceeding to AptameX Trials in Other Countries, Completing its CE Mark Registration to Bring AptameX to Other Parts of Asia, the Midd…